Abstract
Cervical carcinoma is the most common gynecologic tumor in the clinic. The incidence of cervical carcinoma has been increasing in recent years, and the age of the affected population is showing a younger trend. Long-chain noncoding RNA (LncRNA) acts in the cell cycle. In cervical carcinoma, many studies have also confirmed the important role of LncRNA. LncRNA ABHD11-AS1 is one of the genes abnormally expressed in cervical carcinoma, but the specific situation has not been fully explained. This study intended to confirm whether LncRNA ABHD11-AS1 can be applied for the treatment of cervical carcinoma in the future. From January 2015 to January 2017, 72 cases of cervical carcinoma patients and 78 cases of healthy people during the same period in our hospital were selected for prospective analysis. ABHD11-AS1 and miR-1254 in serum and carcinoma tissues of cervical carcinoma patients were detected. In addition, human cervical carcinoma cells HeLa and CaSki were obtained to analyze the effects of interference with ABHD11-AS1 and miR-1254 on the biological behavior of cervical carcinoma cells. Finally, the correlation of ABHD11-AS1 with miR-1254 was verified by double fluorescein reporter enzyme and immunocoprecipitation. ABHD11-AS1 was upregulated, and miR-1254 was reduced in serum and carcinoma tissues of cervical carcinoma patients (P < 0.05). The expression levels of the two were negatively correlated (P < 0.001). ABHD11-AS1 decreased and miR-1254 increased in serum of cervical carcinoma patients after treatment (P < 0.05). High ABHD11-AS1 and low miR-1254 had a close correlation with the poor prognosis of cervical carcinoma patients (P < 0.05). Silencing LncRNA ABHD11-AS1 could inhibit the activity of cervical carcinoma cells (P < 0.05), while inhibiting miR-1254 could promote the activity of cervical carcinoma cells (P < 0.05). ENCORI online website found that LncRNA ABHD11-AS1 and miR-1254 had binding sites. Bifluorescein reporter enzyme experiment found that ABHD11-AS1-WT fluorescence activity was inhibited by transfected miR-1254-mimics (P < 0.05). LncRNA ABHD11-AS1 accelerates proliferation, invasion, and migration of cervical carcinoma cells through targeted regulation of miR-1254, which may become the key to the treatment of cervical carcinoma.
Highlights
Cervical carcinoma has had a rising incidence rate in recent years, and the age of the affected population is showing a younger trend [1, 2]
We found that Long-chain noncoding RNA (LncRNA) ABHD11-AS1 was involved in the occurrence and progression of endometrial carcinoma and has a regulatory effect on the biological behavior of endometrial carcinoma cells [9]
Liu et al [10] found LncRNA ABHD11-AS1 was one of the genes abnormally expressed in cervical carcinoma during gene screening, but the specific situation has not been fully explained. erefore, in order to confirm the situation of LncRNA ABHD11-AS1 in cervical carcinoma and its related mechanism, we first analyzed the downstream genes with binding sites with LncRNA ABHD11-AS1 through ENCORI and found that they include miR-1254
Summary
Cervical carcinoma has had a rising incidence rate in recent years, and the age of the affected population is showing a younger trend [1, 2]. Rough long-term efforts in clinical medicine, we have learned that the occurrence and progression of cervical carcinoma have a close correlation with proliferation, invasion, and migration of carcinoma cells [4]. It is still unclear what exactly affects the activation of carcinoma cells. We found that LncRNA ABHD11-AS1 was involved in the occurrence and progression of endometrial carcinoma and has a regulatory effect on the biological behavior of endometrial carcinoma cells [9]. Erefore, we preliminarily speculated that LncRNA ABHD11-AS1 may affect the process of cervical carcinoma through miR-1254. In order to verify our conjecture, we will carry out an experimental analysis to confirm whether LncRNA ABHD11AS1 can be applied for the treatment of cervical carcinoma in the future
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
